|
"boku n"的相關文件
顯示項目 1-40 / 40 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
| 臺大學術典藏 |
2022-09-07T07:41:47Z |
Present status and perspectives of colorectal cancer in Asia: Colorectal cancer working group report in 30th Asia-Pacific cancer conference
|
Hyodo I.; Suzuki H.; Takahashi K.; Saito Y.; Tanaka S.; HAN-MO CHIU; Kim N.K.; Li J.; Lim R.; Villalon A.; Boku N. |
| 國家衛生研究院 |
2022-04 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
|
Kang, YK;Reck, M;Nghiem, P;Feng, Y;Plautz, G;Kim, HR;Owonikoko, TK;Boku, N;Chen, LT;Lei, M;Chang, H;Lin, WH;Roy, A;Bello, A;Sheng, J |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2022 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
|
Kang, Y.-K.;Reck, M.;Nghiem, P.;Feng, Y.;Plautz, G.;Kim, H.R.;Owonikoko, T.K.;Boku, N.;Chen, L.-T.;Lei, M.;Chang, H.;Lin, W.H.;Roy, A.;Bello, A.;Sheng, J. |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國家衛生研究院 |
2021-09-04 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
|
Kang, YK;Morita, S;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Chen, LT;Boku, N |
| 臺大學術典藏 |
2021-09-01T01:53:56Z |
Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012
|
Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG; Kang Y.-K.; de Lima Lopes G. |
| 臺大學術典藏 |
2021-09-01T01:53:48Z |
Randomized phase iii study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: Gest study
|
Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 臺大學術典藏 |
2021-02-03T03:56:42Z |
Present status and perspectives of colorectal cancer in Asia: Colorectal cancer working group report in 30th Asia-Pacific cancer conference
|
Hyodo I.; Suzuki H.; Takahashi K.; Saito Y.; Tanaka S.; HAN-MO CHIU; Kim N.K.; Li J.; Lim R.; Villalon A.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
|
Chen, LT;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, W;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N |
| 國立成功大學 |
2020 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, L.-T.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Sameshima, H.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-05-13 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T;Kang, YK;Chao, Y;Ryu, MH;Kato, K;Cheol Chung, H;Chen, JS;Muro, K;Ki Kang, W;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Tanimoto, M;Chen, LT;Boku, N |
| 國家衛生研究院 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
|
Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2019 |
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
|
Moehler, Moehler M.;Ryu, M.-H.;Dvorkin, M.;Lee, K.-W.;Coşkun, H.Ş.;Wong, R.;Chung, H.C.;Poltoratsky, A.;Tsuji, A.;Yen, C.J.;Muntean, A.S.;Le, Sourd S.;Vaccaro, G.M.;Overton, L.;Boku, N.;Wainberg, Z.A.;Patel, M.;Sharma, M.;Xiong, H.;Conti, I.;Taieb, J.;Bang, Y.-J. |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2018-12-01 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
|
Kato, K;Satoh, T;Muro, K;Yoshikawa, T;Tamura, T;Hamamoto, Y;Chin, K;Minashi, K;Tsuda, M;Yamaguchi, K;Machida, N;Esaki, T;Goto, M;Komatsu, Y;Nakajima, TE;Sugimoto, N;Yoshida, K;Oki, E;Nishina, T;Tsuji, A;Fujii, H;Kunieda, K;Saitoh, S;Omuro, Y;Azuma, M;Iwamoto, Y;Taku, K;Fushida, S;Chen, LT;Kang, YK;Boku, N |
| 國家衛生研究院 |
2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Haag, GM;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Exposito, MJJ;Janjigian, YY;Boku, N;Chau, I |
| 國家衛生研究院 |
2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, HY;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 國家衛生研究院 |
2017-09 |
ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer
|
Chen, LT;Kang, YK;Tanimoto, M;Boku, N |
| 國家衛生研究院 |
2017-09 |
ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer
|
Terashima, M;Kim, YW;Yeh, TS;Chung, HC;Chen, JS;Boku, N;Kang, YK;Chen, LT;Sasako, M |
| 國家衛生研究院 |
2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
|
Kang, YK;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Boku, N;Chen, LT |
| 國家衛生研究院 |
2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
|
Boku, N;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Chen, LT |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
顯示項目 1-40 / 40 (共1頁)
1
每頁顯示[10|25|50]項目
|
